This trial is enrolling 27 individuals with chronic spinal cord injury to test the effect of Dalfampridine (4-AP) in combination with electrical stimulation and walking training. 4-AP is a potassium channel blocker that may enhance nerve signals. If included, participants will be randomly assigned to receive 40 sessions of either 4-AP or a placebo (taken twice daily), along with stimulation to the spinal cord and peripheral nerves, combined with walking training. Final testing will be performed after 12 weeks. .
Type
Details
- Participants will be randomly assigned to receive either Dalfampridine (4-AP) or a placebo twice daily, along with 40 sessions of stimulation to the spinal cord and peripheral nerves, combined with walking training. - 4-AP is a potassium channel blocker that may enhance nerve signals. - Final testing will be performed after 12 weeks.
Main benefits
General health
Additional benefits
Bladder health/function
Bowel health
Mental health and psychosocial factors
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more